Cerebrolysin

Cerebrolysin is not "no evidence" — multiple randomized controlled trials exist for both acute ischemic stroke and vascular dementia, and Cochrane has reviewed both. But the most current Cochrane reviews conclude it probably has little or no benefit in stroke, and insufficient evidence to recommend routine use in vascular dementia. It is not FDA- or EMA-approved for any use and has no legal US prescription pathway.

What it is

Cerebrolysin is a proprietary mixture of low-molecular-weight peptides and free amino acids enzymatically derived from purified porcine brain tissue, manufactured exclusively by EVER Neuro Pharma (Austria). It's marketed as a "neurotrophic" agent intended to mimic the action of endogenous neurotrophic factors. It is approved as a prescription drug in a large number of countries — commonly cited as 40 or more, including Russia, China, and much of Eastern Europe and Latin America — but has never been approved by the FDA or EMA for any indication.

The acute ischemic stroke evidence

Cochrane's most current review of this question (Ziganshina et al., Cochrane Database Syst Rev 2023, DOI 10.1002/14651858.CD007026.pub7) concluded, with moderate-certainty evidence, that Cerebrolysin probably has no beneficial effect on preventing all-cause death after acute ischemic stroke or on the total number of people with serious adverse events — and found a possible increase in non-fatal serious adverse events. The European Stroke Organisation and European Academy of Neurology guidelines advise against Cerebrolysin use on this basis.

The vascular dementia evidence

Cochrane's current review of this separate question (Cui, Chen, Yang, Guo, Zhou, Zhu, He, Cochrane Database Syst Rev 2019, DOI 10.1002/14651858.CD008900.pub3) found Cerebrolysin may have positive effects on cognitive and global function in patients with mild-to-moderate vascular dementia — but the review's own authors explicitly declined to recommend it as a routine treatment, citing a limited number of trials, varying treatment durations, short follow-up, and risk of bias.

Why the legal picture matters as much as the trial data

Because Cerebrolysin has no FDA approval and no compounding pathway, its US availability runs through personal importation and clinics administering imported product outside any FDA oversight of manufacturing, purity, or labeling for the US market — a materially different risk profile from an approved drug, even where trial data exists, and worth stating plainly rather than letting "approved in 40 countries" imply US-equivalent oversight.